A Prospective Study to Evaluate High Dose Daptomycin Pharmacokinetics and Pharmacodynamics in Spp. Infective Endocarditis

Overview

Journal Ther Adv Infect Dis

Publisher Sage Publications

Date 2025 Jan 10

PMID 39791119

Authors

Simona De Gregori

Annalisa De Silvestri

Mara Capone

Vincenzina Monzillo

Paola Giordani

Raffaele Bruno

Elena Seminari

Affiliations

Soon will be listed here.

Abstract

Background: Daptomycin pharmacokinetics and pharmacodynamics data relative to higher doses in patients are necessary for clinical practice.

Objectives: A monocentric, prospective study that enrolled patients with a diagnosis of spp. infective endocarditis treated with daptomycin according to clinical practice, to evaluate the pharmacokinetics/pharmacodynamics of different daptomycin daily doses (group A: 8-10 and group B: 11-12 mg/kg).

Design And Methods: A monocentric, prospective, cohort study that enrolled patients with a diagnosis of spp. infective endocarditis treated with daptomycin. Daptomycin was administered by intravenous infusion over a 30-min period for at least five consecutive days before PK study.

Results: Twenty-two patients were included. Native valve infectious endocarditis (IE) was diagnosed in 9 patients, prosthetic valve IE was diagnosed in 10 patients and 3 patients had concomitant intracardiac device infections. All patients showed a microbiologic response with negative blood cultures by day 5 (1-3 interquartile rate (IQR) 3-8). The median calculated AUC was 1298 (1-3 IQR 1069-1484) and 1459 (1-3 IQR 1218-1711) µg*h/mL, with the corresponding clearance of 0.49 (1-3 IQR 0.37-0.57) and 0.57 (1-3 IQR 0.40-0.71) L/h, respectively. A value of area under the curve/minimum inhibitory concentration (AUC/MIC) > 666 was reached by all patients; however, 4 out of 15 patients in group A and 1 out of 14 patients in group B did not reach the pharmacokinetic/pharmacodynamic (PK/PD) target of 1061; therefore, AUC/MIC equal to or above 1061 was reached by 73.3% in group A and 92.9% in group B.

Conclusion: From a PK/PD point of view, all patients reached the value of AUC/MIC > 666, while roughly 70% of patients in group A and 90% in group B reached the target value of AUC/MIC>1061. Even if this cut-off value is arbitrary, 11-12 mg/kg daily dose could be taken into consideration in case of serious infections characterised by a high inoculum or in cases of prosthetic valve infections.

References

Gregoire N, Marchand S, Ferrandiere M, Lasocki S, Seguin P, Vourch M . Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother. 2018; 74(1):117-125. DOI: 10.1093/jac/dky374. View

Van Hal S, Paterson D, Gosbell I . Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature. Eur J Clin Microbiol Infect Dis. 2010; 30(5):603-10. DOI: 10.1007/s10096-010-1128-3. View

Senneville E, Caillon J, Calvet B, Jehl F . Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents. 2015; 47(1):12-9. DOI: 10.1016/j.ijantimicag.2015.11.005. View

Dortet L, Anguel N, Fortineau N, Richard C, Nordmann P . In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis. Int J Infect Dis. 2013; 17(11):e1076-7. DOI: 10.1016/j.ijid.2013.02.019. View

Benvenuto M, Benziger D, Yankelev S, Vigliani G . Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006; 50(10):3245-9. PMC: 1610083. DOI: 10.1128/AAC.00247-06. View

Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H . 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023; 44(39):3948-4042. DOI: 10.1093/eurheartj/ehad193. View

Habib G, Erba P, Iung B, Donal E, Cosyns B, Laroche C . Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019; 40(39):3222-3232. DOI: 10.1093/eurheartj/ehz620. View

Kullar R, Casapao A, Davis S, Levine D, Zhao J, Crank C . A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013; 68(12):2921-6. PMC: 3820108. DOI: 10.1093/jac/dkt294. View

De Gregori S, De Silvestri A, Molinaro M, Monzillo V, Biscarini S, Colaneri M . Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. Eur J Drug Metab Pharmacokinet. 2021; 46(4):547-554. DOI: 10.1007/s13318-021-00690-4. View

10.

Garreau R, Pham T, Bourguignon L, Millet A, Parant F, Bussy D . Daptomycin Exposure as a Risk Factor for Daptomycin-Induced Eosinophilic Pneumonia and Muscular Toxicity. Clin Infect Dis. 2023; 77(10):1372-1380. DOI: 10.1093/cid/ciad386. View

11.

Sharma M, Riederer K, Chase P, Khatib R . High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2008; 27(6):433-7. DOI: 10.1007/s10096-007-0455-5. View

12.

Soon R, Turner S, Forrest A, Tsuji B, Brown J . Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agents. 2013; 42(1):53-8. DOI: 10.1016/j.ijantimicag.2013.02.009. View

13.

Carugati M, Bayer A, Miro J, Park L, Guimaraes A, Skoutelis A . High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother. 2013; 57(12):6213-22. PMC: 3837915. DOI: 10.1128/AAC.01563-13. View

14.

Bhavnani S, Ambrose P, Hammel J, Rubino C, Drusano G . Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations. Antimicrob Agents Chemother. 2015; 60(3):1600-7. PMC: 4776011. DOI: 10.1128/AAC.02967-15. View

15.

Samura M, Hirose N, Kurata T, Takada K, Nagumo F, Koshioka S . Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability. Open Forum Infect Dis. 2021; 8(12):ofab568. PMC: 8651170. DOI: 10.1093/ofid/ofab568. View

16.

Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen E, Bocci G . Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents. 2013; 42(3):250-5. DOI: 10.1016/j.ijantimicag.2013.06.006. View

17.

Li J, Sexton D, Mick N, Nettles R, Fowler Jr V, Ryan T . Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000; 30(4):633-8. DOI: 10.1086/313753. View

18.

Bassetti M, Mikulska M, Schenone E, Nicolini L, Viscoli C . Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. Int J Antimicrob Agents. 2009; 34(3):290-1. DOI: 10.1016/j.ijantimicag.2009.04.001. View

19.

Safdar N, Andes D, Craig W . In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2003; 48(1):63-8. PMC: 310158. DOI: 10.1128/AAC.48.1.63-68.2004. View

20.

Barber K, Smith J, Ireland C, Boles B, Rose W, Rybak M . Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrob Agents Chemother. 2015; 59(8):4497-503. PMC: 4505217. DOI: 10.1128/AAC.00386-15. View